On November 25, the 5th "Haiju Talent" Global Innovation and Entrepreneurship Summit grandly opened at the Shanghai West Bund International Expo Center. At the summit venue, Immunowake, as one of the first batch of ten cutting-edge hard-core technology projects, signed an investment intention agreement with the "Haiju Talent" Venture Capital Fund.

The "Haiju Talent" Venture Capital Fund was initiated and established by Shanghai Guotou Corporation. With a target size of RMB 2 billion and an initial size of RMB 300 million, the fund will focus on leading industries such as integrated circuits, biomedicine and artificial intelligence, prioritize high-level sci-tech talent projects, inject strong impetus into scientific and technological innovation with "capital as a vital source of water", and accelerate the transformation of more cutting-edge hard-core technologies from the laboratory to industrialization.

As one of the first two key projects supported by the "Haiju Talent" Venture Capital Fund in the life and health sector, this signing is not only a high recognition of Immunowake's innovative strength, but also an important milestone in the company's development.

Immunowake has built a world-leading original cytokine technology platform and accumulated a systematic and profound research foundation in the field of cytokine immunotherapy. In addition to the award-winning targeted IL-12 immunostimulant project, the company has also demonstrated outstanding competitive advantages and sustained innovation capabilities in the R&D of multiple cytokine projects including IL-2.

In the future, with the support of the "Haiju Talent" Venture Capital Fund, the company will fully promote the IL-12 project to accelerate entry into the clinical phase, while devoting itself to original innovation and continuously achieving new breakthroughs in drug R&D.